Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.44 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.44 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding the company's performance. They emphasized a commitment to long-term goals without offering specific guidance.
Management did not provide specific details on revenue expectations.
The company remains focused on its long-term strategies despite current challenges.
Nektar Therapeutics reported a loss of $0.44 per share, which may raise concerns among investors about the company's profitability. The stock reacted negatively, declining by 2.79%. The lack of revenue data and guidance may contribute to uncertainty about the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ALCON INC
May 5, 2008